CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

Go back to CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

CytoSorbents (CTSO) PT Raised to $18 at Maxim Group

August 3, 2018 7:36 AM EDT

Maxim Group raised its price target on CytoSorbents (NASDAQ: CTSO) to $18.00 (from $13.00) while maintaining a Buy rating.

Analsyt Jason McCarthy commented:

Cytosorbents reported another quarter of growth with Cytosorb revenues of $5.24M, up sequentially from $4.4Mthe 24th consecutive quarter of y/y... More

CytoSorbents (CTSO) PT Raised to $15 at Cowen

August 3, 2018 6:42 AM EDT

Cowen raised its price target on CytoSorbents (NASDAQ: CTSO) to $15.00 (from $13.00) while maintaining an Outperform rating.

Analyst Josuah Jennings commented, "CTSO again delivered impressive quarterly revenue growth, with product sales of $5.2M, up 72% from last year. Lead product CytoSorb has numerous tailwinds in 2018, including (1) favorable German... More

Cytosorbents (CTSO) Misses Q2 EPS by 7c

August 2, 2018 4:51 PM EDT

Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.19), $0.07 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.07 million.

Ended Q2 2018 with $25.3 million in cash and cash equivalents.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

... More